共 50 条
- [41] Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in SpainBLOOD, 2020, 136Costa, Pau AbrisquetaLoscertales, JavierTerol, Maria JosePayer, Angel RamirezPareja, Macarena OrtizPerez, InmaculadaCuellar, CarolinaDe La Mata, Margarita FernandezRodriguez, AliciaLario, AnaDelgado, JulioGodoy, Ana CristinaArguinano, Jose M.Berruezo, Maria JoseOliveira, Ana C.Hernandez-Rivas, Jose AngelGarcia-Malo, Maria-DoloresMedina, AngelesMartin, Paloma GarciaOsorio-Prendes, SantiagoBaltasar, PatriciaFernandez, MiguelMarco, FernandoVidal, Maria-JesusSimonovich, Alicia Susana SmuclerRubio, Montserrat LopezJarque, IsidroCabrera, Alexia SuarezFernandez, RubenAnchel, Aima LancharroHerranz, Eduardo RiosLosada, CarmenPersona, Ernesto PerezGarcia, Ricardo FranciscoRamos, RafaelYanez, LucreciaBello, Jose LuisLoriente, CristinaVillanueva, Miguel
- [42] Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemiaEJHAEM, 2023, 4 (02): : 381 - 392Bouligny, Ian M.Murray, GraemeDoyel, MichaelPatel, TilakBoron, JoshTran, ValerieGor, JuhiHang, YiweiAlnimer, YanalZacholski, KyleVenn, ChadWages, Nolan A.Grant, StevenMaher, Keri R.
- [43] Promise of the obinutuzumab, ibrutinib and venetoclax combination in the first line of high-risk chronic lymphocytic leukemiaHEMATOLOGIE, 2022, 28 (02): : 107 - 108Stocker, Nicolas
- [44] Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in SpainFARMACIA HOSPITALARIA, 2022, 46 (03) : 121 - 132Moreno-Martinez, Estelade la Serna-Torroba, JavierEscudero-Vilaplana, VicenteAngel Hernandez-Rivas, JoseSanchez-Cuervos, MarinaSanchez-Hernandez, Raquel
- [45] Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity StudyBLOOD, 2018, 132Hillmen, PeterRawstron, AndyBrock, KristianVicente, Samuel MunozYates, FrancescaBishop, RebeccaMacdonald, DonaldFegan, ChristopherMcCaig, AlisonSchuh, AnnaPettitt, AndrewGribben, John G.Patten, Piers E. M.Devereux, StephenBloor, AdrianFox, Christopher P.Forconi, FrancescoMunir, Talha
- [46] Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity StudyBRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 25 - 25Munir, T.Rawstron, A.Brock, K.Vicente, S. MunozYates, F.Bishop, R.Macdonald, D.Fegan, C.McCaig, A.Schuh, A.Pettitt, A.Gribben, J. G.Patten, P. E.Devereux, S.Bloor, A.Fox, C. P.Forconi, F.Hillmen, P.
- [47] Ibrutinib Treatment in CLL Interrupts CD40 Signaling Capacity and Sensitizes CLL Cells to VenetoclaxBLOOD, 2021, 138Kielbassa, KarolineHaselager, MarcoBax, DaniqueDubois, JulieLevin, Mark-DavidWesterweel, Peter E.Svanberg, RebeckaNiemann, Carsten UtoftKater, Arnon P.Eldering, Eric
- [48] Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE studyBLOOD ADVANCES, 2023, 7 (18) : 5294 - 5303Moreno, CarolSolman, Isabelle G.Tam, Constantine S.Grigg, AndrewScarfo, LydiaKipps, Thomas J.Srinivasan, SrimathiMali, Raghuveer SinghZhou, CathyDean, James P.Szafer-Glusman, EdithChoi, Michael
- [49] First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free EraCANCERS, 2023, 15 (15)Urso, AntonioCavazzini, FrancescoBallardini, Maria PiaGambara, SilviaConsolo, SaraRigolin, Gian MatteoCuneo, Antonio
- [50] Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)BLOOD, 2021, 138Jain, NitinFerrajoli, AlessandraYilmaz, MusaThompson, Philip A.Konopleva, MarinaGreen, Michael R.Sampath, DeepaNeelapu, Sattva S.Takahashi, KoichiMasarova, LuciaBurger, Jan A.Kanagal-Shamanna, RashmiKhoury, Joseph D.Garg, NaveenSu, XiaopingWang, XuemeiPatel, HinalbenAyala, AnaKantarjian, HagopKeating, Michael J.Wierda, William G.